Vertex = one of the three worst American Stocks:
An all around tough year for a company focusing on treating cystic fibrosis
Vertex Pharmaceuticals doesn't have as clear-cut a catalyst for its downward trend. Instead, there's a collection of factors that combined to nudge the company's stock down throughout the year.
In January, the stock lost 26% of its value. While there wasn't company-specific news to explain the drop, the entire biopharmaceutical industry suffered major losses during the month, as many investors thought these companies were overpriced and hitting "bubble" territory.
Subsequently, the stock dipped on two drug-related announcements. The FDA announced in February that it would need more specific data on Kalydeco before granting expanded uses, and management subsequently offered sales estimates that Wall Street wasn't happy with. And in March, the U.K.'s National Institute for Health and Care Excellence issued draft guidance announcing it wouldn't recommend Orkambi based on its high price, and it confirmed that decision in June.
en vandaag nog iets meer: VRTX Vertex Pharmaceuticals Incorporated
75,34 -2,78 -3,56%